GLP-1 agonists coincide with 71% global rise in anorexia and bulimia incidence 1990-2023

A new epidemiological report documents the 71% rise in combined anorexia and bulimia incidence. Clinicians report GLP-1 drugs such as semaglutide and tirzepatide triggering restrictive behaviors in patients with prior eating-disorder histories. Prescribing guidelines currently contain no mandatory screening for disordered eating despite documented cases of rapid dose escalation and weight cycling after discontinuation.

Prescription volumes for GLP-1 agonists reached 15 million U.S. patients by late 2025. The same interval shows parallel increases in eating-disorder clinic referrals in multiple health systems. Longitudinal cohort data indicate that 12-18% of GLP-1 users with subclinical symptoms progress to clinical thresholds within 12 months, exceeding background rates.

Coverage has treated the 71% incidence increase and GLP-1 rollout as separate trends. The intersection reveals an unmeasured feedback loop: appetite suppression reinforces restriction in vulnerable populations while metabolic adaptation after cessation drives compensatory binge-purge cycles. No large-scale post-marketing study has yet stratified outcomes by baseline eating-disorder status.

Regulatory filings and updated DSM criteria revisions scheduled for 2027 will require explicit comorbidity tracking. Health systems are piloting mandatory pre-prescription validated screeners; results will determine whether labeling changes or REMS programs follow.